Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Spruce Biosciences Inc
Healthcare
P/NCAV
0.36x
Ticker
SPRB
Exchange
NASDAQ
Country
United States
Close
0.7 $
Mkt Cap
27.0M $
EV
-66.0M $
NCAV Burn Rate
-12.5%
Current Ratio
4.18
Debt/Equity
0.04
EV/REV
-6.54x
EV/EBIT
1.3x
EV/FCF
2.0x
Dilution
11.6% p.A
Total Net Income
-188.9M $
Cheapness
1.0%
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The Company also investigates tildacerfont for the treatment of classic CAH in children.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average